文献速递神经肿瘤

中枢神经细胞瘤的长期结局:单中心经验

Long-term outcomes of central neurocytoma - an institutional experience.
PubMed 文献 · J Neurooncol · 2024-06-12

该研究回顾了2001至2021年间22例中枢神经细胞瘤患者的资料,中位随访6.9年,无肿瘤相关死亡。接受次全切除和/或Ki-67>4%的非典型肿瘤患者无复发生存期较短,典型中枢神经细胞瘤5年无复发生存率为67%,非典型为22%。肿瘤复发后挽救性放疗可实现长期肿瘤控制。

要点

  • 中位随访6.9年,22例中枢神经细胞瘤患者无肿瘤相关死亡。
  • 典型中枢神经细胞瘤5年无复发生存率为67%,非典型为22%。
  • 5例儿童肿瘤均为非典型,其中3例在5年内复发。

核心结论

  • 接受全切除或肿瘤复发后放疗的中枢神经细胞瘤患者可获得良好的长期肿瘤控制。

研究设计与样本

  • 回顾性分析2001至2021年间病理诊断为中枢神经细胞瘤的22例患者(17例成人≥18岁,5例儿童<18岁),采用Kaplan-Meier法计算无复发生存期和总生存期,并进行放疗后肿瘤体积消退分析。

主要发现

  • 中位随访6.9年,无肿瘤相关死亡。
  • 接受次全切除和/或Ki-67>4%的非典型肿瘤患者无复发生存期较接受全切除和/或无未成熟肿瘤患者缩短。
  • 典型中枢神经细胞瘤5年无复发生存率为67%,非典型中枢神经细胞瘤为22%。
  • 5例儿童肿瘤均为非典型,其中3例在5年内复发。
  • 肿瘤复发后行挽救性放疗在继续随访期间未见进一步复发,3例复发肿瘤的体积分析显示肿瘤大小约缩小80%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Central Neurocytoma (CN) is a rare, WHO grade 2 brain tumor that predominantly affects young adults. Gross total resection (GTR) is often curative for CNs, but the optimal treatment paradigm including incorporation of RT, following subtotal resection (STR) and for scarcer pediatric cases has yet to be established. METHODS: Patients between 2001 and 2021 with a pathologic diagnosis of CN were reviewed. Demographic, treatment, and tumor characteristics were recorded. Recurrence free survival (RFS) and overall survival (OS) were calculated according to the Kaplan Meier-method. Post-RT tumor volumetric regression analysis was performed. RESULTS: Seventeen adults (≥ 18 years old) and 5 children (< 18 years old) met the criteria for data analysis (n = 22). With a median follow-up of 6.9 years, there was no tumor-related mortality. Patients who received STR and/or had atypical tumors (using a cut-off of Ki-67 > 4%) experienced decreased RFS compared to those who received GTR and/or were without atypical tumors. RFS at 5 years for typical CNs was 67% compared to 22% for atypical CNs. Every pediatric tumor was atypical and 3/5 recurred within 5 years. Salvage RT following tumor recurrence led to no further recurrences within the timeframe of continued follow-up; volumetric analysis for 3 recurrent tumors revealed an approximately 80% reduction in tumor size. CONCLUSION: We provide encouraging evidence that CNs treated with GTR or with RT after tumor recurrence demonstrate good long-term tumor control.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yang Y, Wadhwani N, Shimomura A, et al. Long-term outcomes of central neurocytoma - an institutional experience. J Neurooncol. 2024. PMID: 38865011. doi:10.1007/s11060-024-04713-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。